Coherus Oncology Inc. (CHRS) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Coherus Oncology Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Coherus Oncology Inc. (CHRS) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $165M. It trades at $1.16, up 8.41% today. Its overall quality score is 35 out of 100, ranked against the whole US market. 4 analysts' average target of $7.75 implies +568.1% from today's price. Kronos AI's 30-day forecast is +27.5% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $7.75 |
| Low – high | $4.00 – $10.00 |
| Analysts | 4 |
| Upside to average | +568.1% |
Kronos AI 30-day forecast
| Expected close | $1.36 (+27.5%) |
| Likely range | +17.9% … +44.1% |
| As of | 2026-10-27 |
Quality scores
| Profitability | 6 |
| Solvency | 41 |
| Growth | 58 |
| Overall | 35 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Halal Health Care stocks · Zakat calculator · Purification calculator